Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Inclusion Criteria:

1. PD patients between the ages of 30-85;
2. Patients with Parkinson's disease dyskinesia, and UPDRS 4.2 score ≥ 2 points;
3. The patient diary shows that there are at least two opening periods between 9 am and 4pm every day, and the dyskinesia appears in the opening period, each time lasting morethan half an hour;
4. The treatment plan for anti-Parkinson's disease is stable and not adjusted within 30days before enrollment;
5. Levodopa is administered at least three times a day.

Exclusion Criteria:

1. PD patients with biphasic, dystonia, closure, myoclonus, but no dyskinesia;
2. pregnant and lactating women;
3. Taking other Chinese medicines against Parkinson's disease 2 weeks before enrollment;
4. Impaired cognitive function (according to pre-entry MMSE score): secondary educationlevel: MMSE <24 points; primary education level <20 points; illiterate <17 points;
5. Psychiatric symptoms associated with anti-Parkinson's disease drugs
6. accompanied by a history of mental illness;
7. impaired liver and kidney function;
8. accompanied by severe other systemic diseases;
9. Amantadine treatment has been received within the first 30 days of enrollment;
10. History of medication with apomorphine or dopamine receptor antagonists;
11. Previously taking amantadine, unable to tolerate;
12. Allergic to the amantadine, memantine, and traditional Chinese medicine preparationsor serious adverse reactions;
13. Before the enrollment, the EKG showed obvious abnormalities and required clinicalintervention.
14. has received PD-related brain surgery;
15. Patients who are participating in other clinical studies or have participated in otherclinical studies within the previous 30 days;
16. Patients who are unable to follow up with follow-up.